Mepolizumab  (Synonyms: SB 240563)

Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Mepolizumab shows nearly linear PK after intravenous administration over a 6000-fold dose range (0.05-300 mg/kg), inhibiting eosinophil proliferation with an IC₅₀ of 1.43 mg/mL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mepolizumab shows nearly linear PK after intravenous administration over a 6000-fold dose range (0.05-300 mg/kg), inhibiting eosinophil proliferation with an IC₅₀ of 1.43 mg/mL^[1].
Pharmacokinetic analysis of mepolizumab in cynomolgus monkeys^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

196078-29-2

Liquid

Colorless to light yellow

[Mepolizumab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. P Zia-Amirhosseini, et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther. 1999 Dec;291(3):1060-7.  [Content Brief]

  [2]. Tim Harrison, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020 Oct 15;56(4):2000151.  [Content Brief]

  [3]. Ian D Pavord, From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. Allergy. 2022 Mar;77(3):778-797.  [Content Brief]